| Identification | Back Directory | [Name]
4-((2-(((1R,2R)-2-hydroxycyclohexyl)aMino)benzo[d]thiazol-6-yl)oxy)-N-MethylpicolinaMide | [CAS]
953769-46-5 | [Synonyms]
BLZ945
106245
CS-1735
4-((2-(((1R
BLZ-945 >=95%
BLZ-945;BLZ 945
2R)-2-hydroxycyclohexyl)imino)-2
3-dihydrobenzo[d]thiazol-6-yl)oxy)-N-methylpicolinamide
4-((2-(((1R,2R)-2-hydroxycyclohexyl)aMino)benzo[d]thiazol-6-yl)oxy)-N-MethylpicolinaMide
4-[[2-[[(1R,2R)-2-Hydroxycyclohexyl]amino]-6-benzothiazolyl]oxy]-N-methylpyridine-2-carboxamide
4-((2-(((1R,2R)-2-hydroxycyclohexyl)aMino)benzo[d]thiazol-6-yl)oxy)-N-MethylpicolinaMide
BLZ945
4-[[2-[[(1R,2R)-2-Hydroxycyclohexyl]amino]-6-benzothiazolyl]oxy]-N-methyl-2-pyridinecarboxamide
2-Pyridinecarboxamide, 4-[[2-[[(1R,2R)-2-hydroxycyclohexyl]amino]-6-benzothiazolyl]oxy]-N-methyl-
4-((2-(((1R,2R)-2-hydroxycyclohexyl)aMino)benzo[d]thiazol-6-yl)oxy)-N-MethylpicolinaMide USP/EP/BP
4-[(2-{[(1R,2R)-2-Hydroxycyclohexyl]amino}-1,3-benzothiazol-6-yl)oxy]-N-methyl-2-pyridinecarboxamide
4-[[2-[[(1R,2R)-2-hydroxycyclohexyl]amino]-1,3-benzothiazol-6-yl]oxy]-N-methylpyridine-2-carboxamide | [Molecular Formula]
C20H22N4O3S | [MDL Number]
MFCD28142668 | [MOL File]
953769-46-5.mol | [Molecular Weight]
398.479 |
| Chemical Properties | Back Directory | [density ]
1.377±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
insoluble in EtOH; insoluble in H2O; ≥19.9 mg/mL in DMSO | [form ]
solid | [pka]
13.92±0.46(Predicted) | [color ]
Pale yellow | [InChIKey]
ADZBMFGQQWPHMJ-RHSMWYFYSA-N | [SMILES]
C1(C(NC)=O)=NC=CC(OC2C=C3SC(N[C@@H]4CCCC[C@H]4O)=NC3=CC=2)=C1 |
| Hazard Information | Back Directory | [Uses]
BLZ945 is a tumor-associated macrophage targeting the treatment of glioblastoma multiforme, a most common type of aggresive brain cancer. | [in vivo]
Mice are treated with Sotuletinib or vehicle, and evaluated for symptom-free survival. Median survival in the vehicle-treated cohort is 5.7 weeks. In striking contrast, Sotuletinib significantly improves long-term survival. This endpoint is chosen because Ink4a/Arf / mice develop spontaneous tumors, including lymphomas and sarcomas, beginning at ~30 weeks. Sotuletinib is well-tolerated over long-term treatment, with no visible side-effects, consistent with histopathological studies. Histological grading revealed high-grade, invasive gliomas in all vehicle-treated mice. By contrast, Sotuletinib-treated animals have significantly less-malignant tumors, and no detectable lesions in 55.6% of asymptomatic mice at the endpoint[1]. Mice receiving Sotuletinib shows reduced CSF1R staining in both cervical tumors and the associated stroma, with a significant decrease in CSF1R+ stromal macrophages relative to vehicle-treated mice (P<0.05)[2]. | [storage]
+4°C |
|
|